Fractyl Health (NASDAQ:GUTS) Shares Down 1.1%

Fractyl Health, Inc. (NASDAQ:GUTS) traded down 1.1% during mid-day trading on Thursday . The company traded as low as $6.51 and last traded at $6.57. 69,309 shares were traded during mid-day trading, a decline of 82% from the average session volume of 383,212 shares. The stock had previously closed at $6.64.

Analyst Upgrades and Downgrades

A number of research firms have commented on GUTS. Bank of America assumed coverage on Fractyl Health in a research note on Tuesday, February 27th. They set a “buy” rating and a $26.00 price objective on the stock. Evercore ISI initiated coverage on Fractyl Health in a research report on Wednesday, February 28th. They issued an “outperform” rating on the stock. Finally, Morgan Stanley initiated coverage on shares of Fractyl Health in a research report on Tuesday, February 27th. They set an “overweight” rating and a $18.00 price objective for the company.

Fractyl Health Price Performance

The business has a 50 day simple moving average of $7.74.

Insider Buying and Selling

In other Fractyl Health news, Director Ajay Royan bought 333,333 shares of the stock in a transaction on Tuesday, February 6th. The stock was purchased at an average price of $15.00 per share, with a total value of $4,999,995.00. Following the completion of the purchase, the director now owns 1,251,900 shares in the company, valued at $18,778,500. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.